{"filing":{"accession_number":"0000950103-26-016061","cik":"0001809196","ticker":"IMTX","company_name":"Immatics N.V.","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"dp255331_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1809196/000095010326016061/dp255331_6k.htm"},"events":[{"id":37427,"run_id":34499,"accession_number":"0000950103-26-016061","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit is a Phase 1 clinical trial presentation for IMA203CD8, Immatics' PRAME-directed TCR T-cell therapy, disclosing efficacy and safety results from a multicenter study (IMA203-101). The presentation reports a 51% objective response rate (ORR) across 90 evaluable patients with PRAME+ solid tumors, including gynecologic cancers, melanoma, and synovial sarcoma, with manageable tolerability and no dose-limiting maximum tolerated dose reached. This represents material clinical progress on a key pipeline asset that would affect investor assessment of the company's development trajectory and competitive position in cell therapy.","company_name":"Immatics N.V.","ticker":"IMTX","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42134,"accession_number":"0000950103-26-016061","item_number":"EX-99.1","item_title":"dp255331_ex9901.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a Phase 1 clinical trial presentation for IMA203CD8, Immatics' PRAME-directed TCR T-cell therapy, disclosing efficacy and safety results from a multicenter study (IMA203-101). The presentation reports a 51% objective response rate (ORR) across 90 evaluable patients with PRAME+ solid tumors, including gynecologic cancers, melanoma, and synovial sarcoma, with manageable tolerability and no dose-limiting maximum tolerated dose reached. This represents material clinical progress on a key pipeline asset that would affect investor assessment of the company's development trajectory and competitive position in cell therapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:31:38.415434+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42134,"accession_number":"0000950103-26-016061","item_number":"EX-99.1","item_title":"dp255331_ex9901.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a Phase 1 clinical trial presentation for IMA203CD8, Immatics' PRAME-directed TCR T-cell therapy, disclosing efficacy and safety results from a multicenter study (IMA203-101). The presentation reports a 51% objective response rate (ORR) across 90 evaluable patients with PRAME+ solid tumors, including gynecologic cancers, melanoma, and synovial sarcoma, with manageable tolerability and no dose-limiting maximum tolerated dose reached. This represents material clinical progress on a key pipeline asset that would affect investor assessment of the company's development trajectory and competitive position in cell therapy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:31:38.415434+00:00","company_name":"Immatics N.V.","ticker":"IMTX","filing_date":"2026-10-23"}]}